This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurogenetics  • Oncology  • Brain Cancer  • Statistics and Research Methods  • Prognosis/ Outcomes  • Drug Therapy  • Drug Therapy, Other  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Toward Personalized Therapy

Howard Colman, MD, PhD; Ken Aldape, MD

Arch Neurol. 2008;65(7):877-883.

Recent therapeutic advances have improved standard treatment for patients with newly diagnosed glioblastoma. Unfortunately, even with these improvements, only a fraction of patients derive significant benefit and experience prolonged survival. These findings are consistent with long-standing clinical and recent molecular evidence that subtypes of glioblastoma exist with differing survival rates and response to treatment. However, patients with newly diagnosed glioblastoma are currently treated in a uniform fashion, without regard for potential underlying differences in molecular alterations or prognosis. In this review, we will discuss recent progress toward the identification of robust and clinically relevant molecular subgroups of glioblastoma and initial steps in using this information to individualize therapy and overcome treatment resistance.

Author Affiliations: Departments of Neuro-oncology (Dr Colman) and Pathology (Dr Aldape), and Brain Tumor Center (Drs Colman and Aldape), University of Texas M. D. Anderson Cancer Center, Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(7):871-872.
FULL TEXT